Pre-Clinical Testing

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

08/07/2024

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307,a potentially first-in-class M1…

AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion

03/27/2024

The deal is the third recent buyout of a radiopharmaceutical developer in recent months, following similar deals from Eli Lilly and Bristol Myers Squibb. Excerpt from the Press Release: AstraZeneca is the latest large pharmaceutical company to make a sizable bet on radiopharmaceutical drugs for cancer, agreeing on Tuesday to acquire longtime biotechnology partner Fusion…

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

02/09/2024

Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of Phase 1 Clinical Trial Expected to Occur in the First Half of 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq:…

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease

12/22/2023

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase…

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

11/17/2023

– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease…

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

11/13/2023

Phase 1 trial underway for Terns’ first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24 Oral GLP-1R agonist offers potential for weight loss and improved convenience compared to currently marketed injectables Excerpt from the Press Release: FOSTER CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc.…

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

10/25/2023

RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) – – RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – – RaniPill® HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards – Excerpt from the Press Release: SAN JOSE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE)…

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

10/20/2023

– Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study – Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection…

Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

08/29/2023

– NB-4746 is being developed as a neuroprotective therapy for neurological diseases – Milestone marks Nura Bio’s transition to a clinical-stage company Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation…

Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS

08/23/2023

Excerpt from the Press Release: SAN DIEGO, Aug. 17, 2023 /PRNewswire/ — Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis for neurological diseases, today announced positive results from its Phase 1 clinical study in healthy volunteers that demonstrate a favorable safety,…